CERCARE MEDICAL APS

Their core work

Cercare Medical (operating as Mindway AI) is a Danish medtech SME developing artificial intelligence software for acute stroke diagnosis and treatment decisions. Their core technology uses neural networks to predict hemorrhagic transformation in stroke patients and support time-critical treatment of acute ischaemic stroke. The company progressed from feasibility (SME Instrument Phase 1) to full development (Phase 2), indicating validated commercial potential in AI-assisted stroke care. Their work sits at the intersection of medical imaging, machine learning, and emergency neurology.

What they specialise in

How they've shifted over time

Cercare Medical's H2020 trajectory shows a focused, deepening specialization rather than a broadening of scope. Starting in 2017 with a small feasibility study on acute stroke treatment timing (iTRUST Phase 1) and parallel AI prediction research (TreatStroke), they secured major Phase 2 funding in 2019 to scale the iTRUST solution. This is a textbook SME Instrument success story — validating a concept, then investing heavily in product development.

Moving from research validation toward commercial medical AI product for stroke diagnosis, likely approaching or at market entry stage post-2021.

How they like to work

Cercare Medical operated exclusively as a sole coordinator across all three projects, with zero consortium partners recorded. This is typical for SME Instrument grants, which fund individual companies rather than consortia. Working with them likely means engaging a focused, independent team that drives its own R&D agenda rather than fitting into large collaborative structures.

No consortium partnerships recorded in H2020 data — all three projects were single-beneficiary SME Instrument grants. Their collaboration network, if any, exists outside the H2020 framework.

What sets them apart

Cercare Medical combines deep specialization in acute stroke neurology with practical AI/machine learning capability — a narrow but high-impact niche. Their successful Phase 1 to Phase 2 progression under the SME Instrument demonstrates that EU evaluators validated both the technology and the business case. For potential partners, they offer a rare combination: a small, agile team with domain-specific medical AI expertise backed by nearly €2M in EU-validated development funding.

Highlights from their portfolio

• iTrust
  Largest project at €1.83M (SME Instrument Phase 2), representing the scale-up of their core stroke treatment timing technology after successful Phase 1 validation.
• TreatStroke
  Explicitly focused on artificial neural network prediction of hemorrhagic transformation — the most technically specific of their projects, revealing the AI methodology behind their platform.